EQT: Australia's Top Trustee — The Franchise the Market Has Written Off
EQT: Australia's Top Trustee — The Franchise the Market Has Written Off
In a Nutshell
Executive Summary
In a Nutshell
EQT Holdings is Australia's dominant independent trustee and responsible entity, earning fee income from administering superannuation funds, managed investment schemes, and deceased estates. At A$22.44 versus fair value A$31.45, the stock is undervalued by 40%. The market prices EQT at break-up value — assigning zero going-concern premium to a growing core franchise — and resolution of ASIC's Shield litigation is the catalyst to close that gap.
Investor Profiles
| Profile | Rating | Rationale |
|---|---|---|
| Income | ★★★☆☆ | FY26E DPS of $1.09 at the current price yields 4.9%, fully franked — a gross yield of roughly 7%. Free cash flow covers the dividend comfortably at a 75% payout ratio. However, FY27E DPS dips to $0.98 as earnings trough through the STS wind-down; income investors should expect a temporary step-down before recovery. Adequate for income, but not reliable enough for pure income mandates given the litigation uncertainty. |
| Value | ★★★★☆ | EQT trades at 8.1x EV/EBITDA against a peer median of 11x — a 26% discount with no permanent structural justification beyond litigation. The break-up value of $22.45 sits at today's share price, providing a hard floor. Fair value of $31.45 implies 40% upside without requiring heroic assumptions. The catalyst is time-bound and binary: Shield resolution unlocks the going-concern premium the market currently denies. |
| Growth | ★★☆☆☆ | Group revenue dips 0.8% in FY27E as the STS wind-down offsets CTS momentum, before recovering to 2.9% growth in FY28E. CTS itself grows at 15% annually, but this is obscured at the consolidated level. EQT is not a traditional growth stock — it is a value situation with a structural growth sub-segment emerging beneath the surface. Not suited to pure growth mandates. |
| Quality | ★★★☆☆ | ROIC of 15% exceeds the 9% cost of capital by six percentage points, and the regulatory moat — AFSL and RSE licences, appointment tenure, post-AET scale — is genuinely wide. Management delivered the AET integration on time and on budget. The Shield litigation and three years of unexecuted M&A roll-up strategy are the quality detractors that hold this below a top-tier quality rating. |
| Thematic | ★★★★☆ | Mandatory superannuation (currently $3.5 trillion, forecast to reach $11.3 trillion by 2043) and rising regulatory complexity are structural demand drivers for EQT's services — every new compliance rule creates new outsourcing need. ETF and listed investment trust growth drives CTS appointments at a secular pace. Intergenerational wealth transfer is amplifying the TWS pipeline. Strong thematic alignment for investors positioned around Australia's wealth accumulation story. |
Value investors are the natural owners of EQT at current prices. The 26% EV/EBITDA discount to peers, a hard break-up floor at today's price, and a time-bound binary catalyst in Shield resolution create a classic value setup: identifiable downside protection, a clear re-rating trigger, and patience as the primary edge. The 40% upside to fair value requires no heroic assumptions about the business — it simply requires the litigation overhang to lift.
Executive Summary
EQT Holdings is the firm that stands behind superannuation funds, managed investment schemes, and deceased estates as Australia's dominant independent licensed steward of assets. It earns fee income tied to the assets it governs, the regulatory complexity it manages, and the estates it administers. Revenue is highly recurring; clients cannot easily leave because changing trustee requires a unitholder vote or APRA approval.
The most recent half-year saw revenue of $100m and a pre-tax profit margin of 30.3% — a strong result, partly boosted by an unusually large cohort of high-value estate appointments. The core CTS franchise grew funds under management, administration, and supervision to $283.7bn, up 28% year-on-year, with 41 new scheme appointments in the half. Litigation noise has not impaired the pipeline.
Two headwinds define the near term. ASIC's Shield litigation carries a $73m contingent liability with an uncertain resolution timeline. The STS superannuation administration business is in wind-down following HUB24's insourcing decision, depressing FY27 group revenue. Neither affects the CTS franchise, which is the heart of the thesis.
At A$22.44 versus fair value A$31.45, the stock is undervalued by 40%.
Results & Outlook
What happened?
EQT's first-half FY26 result was ahead of expectations. Revenue of $100m and pre-tax profit of $30.3m produced a 30.3% margin — above the historical average. TWS benefited from a large cohort of high-value estates, a recurring but lumpy source. CTS continued expanding, with FUMAS reaching $283.7bn and 41 new scheme appointments in the period — confirming the pipeline remains intact despite ongoing ASIC proceedings. STS revenue declined on plan as HUB24's insourcing progressed.
| Metric | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|
| Revenue ($m) | 182.5 | 195.0 | 193.4 | 199.1 |
| EBITDA ($m) | 63.3 | 67.9 | 61.6 | 63.7 |
| EBITDA Margin | 34.7% | 34.8% | 31.8% | 32.0% |
| EPS ($) | 1.36 | 1.45 | 1.30 | 1.38 |
| DPS ($, fully franked) | 1.10 | 1.09 | 0.98 | 1.03 |
| FUMAS ($bn) | 221.7 | 283.7 | — | — |
What's next?
FY27 will be the earnings trough. STS revenue falls from $35m in FY26E to $18m as the HUB24 transition completes, pulling group revenue 0.8% lower and compressing EBITDA margins to 31.8%. CTS, growing at 15% annually, begins to absorb the gap from FY28 as STS becomes immaterial to the group.
EQT has launched a formal strategic review of STS. A disposal at or near book value by the second half of calendar 2026 would remove the revenue drag and the impairment risk simultaneously. Shield Federal Court directions are expected in Q2–Q3 CY2026; any indication of settlement discussions would be a material positive. The full-year FY26 result in August 2026 is the next major information event. The metric that matters most is CTS new appointments — sustained above 35 per half confirms the structural thesis is intact.
Valuation & Risks
| Method | Fair Value | Weight |
|---|---|---|
| DCF — Probability-Weighted | A$36.37 | 48% |
| Trading Multiples | A$27.20 | 32% |
| Transaction Comparables | A$30.00 | 12% |
| Asset-Based | A$21.16 | 8% |
| Weighted Fair Value | A$31.45 | |
| Current Price | A$22.44 | |
| Upside | +40% |
What could go wrong?
The primary risk is an adverse outcome in ASIC's Shield litigation. The contingent liability is $73m, and the severe tail — an adverse court judgment accompanied by APRA imposing licence conditions on ETSL's RSE licence — implies fair value of A$12.67, a 44% decline from today's price. That scenario carries an 8% probability. A more probable bear case (22% probability) — Shield costs escalating to around $20m combined with one or two further platform insourcing decisions following HUB24 — implies fair value of A$26.83, still above today's price but with meaningful margin compression. Investors should treat Shield court dates and any platform insourcing announcement as the primary early warning indicators. A 90% confidence interval spanning A$20.44 to A$42.46 reflects genuine uncertainty; this is a catalyst-dependent thesis, not a set-and-forget holding.